Sally Stenning

Gilbert et al Suppl data from Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma

Duncan C. Gilbert, Reem Al‐Saadi, Khin Thway, Ian Chandler et autres

Table 1 from Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

Elizabeth Smyth, Shenli Zhang, David Cunningham, Andrew Wotherspoon et autres

Data from Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

Elizabeth Smyth, Shenli Zhang, David Cunningham, Andrew Wotherspoon et autres

Data from Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma

Duncan C. Gilbert, Reem Al‐Saadi, Khin Thway, Ian Chandler et autres

Data from Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma

Duncan C. Gilbert, Reem Al‐Saadi, Khin Thway, Ian Chandler et autres

Data from Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

Elizabeth Smyth, Shenli Zhang, David Cunningham, Andrew Wotherspoon et autres

Table 1 from Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

Elizabeth Smyth, Shenli Zhang, David Cunningham, Andrew Wotherspoon et autres

Gilbert et al Suppl data from Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma

Duncan C. Gilbert, Reem Al‐Saadi, Khin Thway, Ian Chandler et autres

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Johnathan Joffe, Fay Cafferty, Laura Murphy, Gordon Rustin et autres

gb (code pays fourni par la source)

Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review

William J Cragg, Caroline Hurley, Victoria Yorke-Edwards, Sally Stenning

gb, ie (code pays fourni par la source)

Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST).

Johnathan Joffe, Fay Cafferty, Laura Murphy, Gordon Rustin et autres

gb (code pays fourni par la source)

Assessing the potential for prevention or earlier detection of on-site monitoring findings from randomised controlled trials: Further analyses of findings from the prospective TEMPER triggered monitoring study

William J Cragg, Caroline Hurley, Victoria Yorke-Edwards, Sally Stenning

gb, ie (code pays fourni par la source)